Merck Announces Full-Year And Fourth-Quarter 2012 Financial Results

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2012.
   
$ in millions, except EPS amounts  

Fourth Quarter 2012
 

Fourth Quarter 2011
 

Year Ended Dec. 31, 2012
 

Year Ended Dec. 31, 2011
Sales   $11,738   $12,294   $47,267   $48,047
GAAP EPS   0.46   0.49   2.16   2.02

Non-GAAP EPS that excludes items listed below 1
  0.83   0.97   3.82   3.77

GAAP Net Income 2
  1,401   1,512   6,661   6,272

Non-GAAP Net Income that excludes items listed below 1,2
  2,540   2,978   11,743   11,697

Non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the fourth quarter of $0.83 and $3.82 for the full year of 2012 exclude acquisition-related costs and restructuring costs.

If you liked this article you might like

'Date' These Potential Biotech Winners

'Date' These Potential Biotech Winners

The 10 Stocks America's Biggest Hedge Funds Are Dumping Like Crazy

Why You Keep Cash on Hand; No Downside Conviction -- Jim Cramer's Top Thoughts